PP11 Inhibitors
Chemical inhibitors of PP11 function by targeting various signaling pathways and kinases that are crucial for PP11's activity. Staurosporine, a potent kinase inhibitor, directly blocks the ATP binding site on PP11, which is necessary for its enzymatic activity. This inhibition is a direct approach, preventing PP11 from performing its kinase function. Similarly, Bisindolylmaleimide I and GF109203X, both being the same compound, selectively inhibit protein kinase C (PKC). Since PKC is essential for the phosphorylation events that activate PP11, the inhibition of PKC leads to decreased PP11 activity. In addition, LY294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases (PI3K), disrupt the PI3K/AKT pathway, leading to a reduction in PP11 activity. This is due to the role of AKT in phosphorylating and activating PP11.
Further, H-89 targets protein kinase A (PKA), diminishing the PKA-mediated phosphorylation that is necessary for PP11's regulation. PD98059 and U0126, as MEK inhibitors, obstruct the MAPK/ERK pathway, which is upstream of PP11. This disruption leads to reduced activation of PP11, which is a downstream effector in this pathway. SB203580 acts by inhibiting p38 MAP kinase, another pathway that influences PP11 activity, particularly in response to stress and cytokine production. SP600125, by inhibiting c-Jun N-terminal kinase (JNK), indirectly affects PP11 activity, which is modulated by JNK signaling. Lastly, Rapamycin inhibits mTOR, which controls several downstream pathways affecting PP11 activity, while Triciribine specifically targets the AKT pathway, thus indirectly diminishing PP11 activity. These inhibitors collectively contribute to the modulation of PP11 activity through various signaling mechanisms and kinase interactions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It inhibits PP11 by preventing ATP binding to the kinase domain, which is essential for the protein's kinase activity. This leads to a direct inhibition of PP11's enzymatic function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I selectively inhibits protein kinase C (PKC), which is necessary for phosphorylation events within certain signaling pathways. Inhibition of PKC can decrease PP11 activity as phosphorylation is critical for PP11 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. By inhibiting PI3K, it reduces the downstream signaling required for PP11 activation, leading to a reduction in PP11 kinase activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the mitogen-activated protein kinase (MAPK/ERK) pathway. By inhibiting MEK, which is upstream of ERK, PD98059 can reduce the activation of PP11, as PP11 is a downstream effector in the MAPK/ERK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, which, like PD98059, inhibits the MAPK/ERK pathway and therefore reduces the activation of PP11 by disrupting the signaling cascade necessary for its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase can decrease PP11 activity, as PP11 is involved in the p38 MAPK signaling pathway, which is important for stress responses and cytokine production. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002. By inhibiting PI3K, it disrupts the PI3K/AKT pathway, reducing the phosphorylation and thus the activity of PP11, which is known to be influenced by AKT signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in the regulation of apoptosis and cell proliferation. By inhibiting JNK, SP600125 indirectly reduces PP11 activity which is modulated by JNK signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and proliferation. As mTOR can control the activity of PP11 through downstream signaling pathways, inhibition of mTOR by Rapamycin results in decreased PP11 activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the activation of AKT, which is involved in survival and growth pathways. By inhibiting AKT, Triciribine indirectly inhibits PP11 activity, as PP11 is a downstream target of AKT. | ||||||